Biotest AG
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
BIO3 | F
Overview
Corporate Details
- ISIN(s):
- DE0005227201 (+1 more)
- LEI:
- 529900JVX7RPXBLYUD89
- Country:
- Germany
- Address:
- Landsteinerstraße 5, 63303 Dreieich
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Biotest AG is a global biopharmaceutical company that develops, manufactures, and markets plasma protein products and biotherapeutic drugs. The company's value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine to treat conditions such as haemophilia, immune deficiencies, and severe infections. Biotest also produces Human Serum Albumin for use as an excipient in biotechnological, pharmaceutical, and diagnostic applications. The company maintains an active development pipeline for next-generation immunoglobulins and other therapies. Since 2022, Biotest has been part of the Grifols group.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-09 17:30 |
Regulatory News Service
Biotests Yimmugo launches in the United States
|
English | 7.4 KB | ||
| 2025-09-19 15:00 |
Pre-Annual General Meeting Information
Biotest AG: Extraordinary general meeting convened at the request of Grifols S.…
|
English | 6.3 KB | ||
| 2025-09-17 00:00 |
Registration Form
Articles of association - as of July 02, 2025
|
English | 133.4 KB | ||
| 2025-08-04 13:00 |
Legal Proceedings Report
Biotest AG receives a request from Grifols S.A. to convene an extraordinary gen…
|
English | 6.8 KB | ||
| 2025-07-02 18:08 |
Post-Annual General Meeting Information
Biotest AG: Annual General Meeting approves dividend distribution
|
English | 7.8 KB | ||
| 2025-06-23 17:03 |
Earnings Release
Biotests positive fibrinogen phase III trial results published in The Lancets e…
|
English | 14.5 KB | ||
| 2025-06-20 00:00 |
Regulatory News Service
Berichtigung der Veröffentlichung vom 17.04.2025
|
German | 303.6 KB | ||
| 2025-06-03 16:51 |
Delisting Announcement
Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with …
|
English | 8.2 KB | ||
| 2025-05-28 17:00 |
Board/Management Information
Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
|
English | 8.1 KB | ||
| 2025-05-12 17:35 |
Earnings Release
Biotest confirms Guidance for 2025
|
English | 11.5 KB | ||
| 2025-05-12 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2025
|
English | 414.7 KB | ||
| 2025-05-05 00:00 |
Remuneration Information
Bericht zur Gleichstellung und Entgeltgleichheit nach EntgTranspG als Anlage de…
|
German | 11.9 KB | ||
| 2025-04-16 00:00 |
Regulatory News Service
Berichtigt am 17.06.2025
|
German | 424.7 KB | ||
| 2025-03-31 07:00 |
Earnings Release
Biotest AG increases sales by 6% in financial year 2024
|
English | 13.8 KB | ||
| 2025-03-31 00:00 |
Annual Report
Annual financial report 2024
|
English | 3.0 MB |
Automate Your Workflow. Get a real-time feed of all Biotest AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Biotest AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-29 | Bernöster, Dr. Katrin | Other | Sell | None | 15,640.00 EUR |
| 2021-11-29 | Realsoul Holding S.A. | Close relation | Buy | None | 1,713.60 EUR |
| 2021-11-18 | Fleck, Stephan | Other | Sell | None | 120,870.00 EUR |
| 2021-11-18 | Schüttrumpf, Dr. Jörg | Other | Sell | None | 99,895.50 EUR |
| 2021-11-18 | Reinecke, Dr. Martin | Other | Sell | None | 37,715.00 EUR |
| 2021-11-18 | Moritz, Michael | Other | Sell | None | 35,460.00 EUR |
